cabozantinib,atezolizumab
roche
['contact-03', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo', 'cabozantinib']
great discussion at the oral abstract session for rcc
no added benefit in adding atezo to cabozantinib post progression with prior icis: contact-03 negative trial but important qn answered long term follow up data remains good for io + tki in int/ poor risks #asco23 
Medical Oncologist, Tan Tock Seng Hospital Singapore with subspecialty interests in thoracic and GU oncology